Henry Schein (NASDAQ:HSIC – Free Report) had its target price upped by Piper Sandler from $91.00 to $95.00 in a report published on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.
A number of other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Wall Street Zen lowered Henry Schein from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Thursday, June 11th. Robert W. Baird set a $97.00 price target on shares of Henry Schein in a research report on Wednesday, May 6th. Finally, Mizuho lowered their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $89.36.
View Our Latest Research Report on Henry Schein
Henry Schein Stock Performance
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts expect that Henry Schein will post 5.32 earnings per share for the current year.
Insider Transactions at Henry Schein
In other news, Director William K. Daniel bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the purchase, the director directly owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.89% of the company’s stock.
Institutional Investors Weigh In On Henry Schein
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL purchased a new stake in Henry Schein during the 3rd quarter valued at about $15,375,000. Heartland Advisors Inc. acquired a new stake in Henry Schein in the 4th quarter valued at about $9,070,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Henry Schein by 15.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 115,279 shares of the company’s stock worth $8,856,000 after purchasing an additional 15,765 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Henry Schein by 10,448.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 42,193 shares of the company’s stock valued at $3,189,000 after purchasing an additional 41,793 shares during the last quarter. Finally, Jefferies Financial Group Inc. lifted its position in Henry Schein by 365.6% during the fourth quarter. Jefferies Financial Group Inc. now owns 41,903 shares of the company’s stock worth $3,167,000 after buying an additional 32,903 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Featured Stories
- Five stocks we like better than Henry Schein
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
